Last reviewed · How we verify
NCT06025240: HLA-AB
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
trial testing cf-DNA in Kidney Transplant in 282 participants. Currently enrolling.
13 October 2025
Quick facts
| Lead sponsor | Liverpool University Hospitals NHS Foundation Trust |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 282 |
| Start date | 13 October 2023 |
| Primary completion | 13 October 2025 |
| Estimated completion | 13 October 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- cf-DNA
- Immunological Events following renal transplant in older age
- Determining Predictive Models for Post-transplant HLA-specific Antibody Formation
Conditions studied
- Kidney Transplant — all drugs for Kidney Transplant →
- Renal Transplant Failure — all drugs for Renal Transplant Failure →
- Kidney Transplant Rejection — all drugs for Kidney Transplant Rejection →
- Frailty — all drugs for Frailty →
Sponsor
Liverpool University Hospitals NHS Foundation Trust
Who can join
18 and older, any sex, with Kidney Transplant or Renal Transplant Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel Biomarkers for Rejection in Kidney Transplantation: A Comprehensive Review.
Strader M, Kant S. · · 2025 · cited 1× · PMID 40807111 · DOI 10.3390/jcm14155489 -
A novel INDEL-based next-generation sequencing assay for monitoring donor-derived cell-free DNA in renal transplant recipients-from bedside to results: a UK pilot study.
Nita GE, Partheniou F, Ridgway D, Mehra S, et al · · 2025 · PMID 40275699 · DOI 10.4285/ctr.25.0004
Verify or expand the search:
- PubMed search for NCT06025240
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of cf-DNA
Trials testing the same drug.
- NCT05372549 — Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation · NA · completed
Other recruiting trials for Kidney Transplant
Currently open trials in the same condition.
- NCT07532382 — Personalized Stories for Pediatric Kidney Recipients · recruiting
- NCT07348458 — Kidney Protective Jacket · NA · recruiting
- NCT07333495 — A Mixed Cohort, Multicentre Exploratory Study of Non-invasive Quantitative Assessment of Renal Graft Function With Non-c · recruiting
- NCT06919003 — Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE · Phase 2 · recruiting
- NCT07205692 — Multimorbidity and Cardiovascular Risk Factors After Renal Transplant · recruiting
Other Liverpool University Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07391553 — Achilles Tendon Rupture Patient Outcomes at 12 Months · not yet recruiting
- NCT07034469 — Air Tamponade Versus Fluorinated Gas Tamponade for Rhegmatogenous Retinal Detachment · NA · not yet recruiting
- NCT06566638 — Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction o · NA · not yet recruiting
- NCT06600620 — Intelligent Monitoring to Predict Atrial Fibrillation · suspended
- NCT06271031 — Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infe · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06025240 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liverpool University Hospitals NHS Foundation Trust
- Last refreshed: 30 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06025240.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing